Abstract
Graft versus host disease (GVHD) remains the major cause of morbidity and nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (HSCT). Although the understanding of its biological basis is continuously improving and candidate target pathways therefore increasingly emerge, severe, steroid-refractory GVHD remains an unsolved issue with a rather poor prognosis in clinical practice thus far. With the exception of the Janus kinase (JAK) 1/2 inhibitor, ruxolitinib, which has demonstrated considerable effectiveness in steroid-refractory GVHD in a multicenter survey, few advances have been recognized in this field during recent years. Therefore, developments toward better, more individualized GVHD prophylaxis are needed. This, however, requires a more precise knowledge of risk factors for severe GVHD. One such emerging risk factor is the homozygosity for HLA-C group 1 killer cell immunoglobulin-like receptor (KIR) ligands. In addition, ongoing investigation into the predictive value of immunogenetic polymorphisms and post-transplant biomarkers will contribute to individually designed and adaptable GVHD management in the future, hopefully relying mainly on prophylactic and pre-emptive measures.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroidrefractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey. Leukemia. 2015;29:2062–2068.
Teshima T, Reddy P, Zeiser R. Acute graft-versus-host disease: novel biological insights. Biol Blood Marrow Transplant. 2016 Jan; 22(1):11; doi:10.1016/j.bbmt.2015.10.001.
Kröger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43–53.
Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–864.
Ludajic K, Balavarca Y, Bickeböller H, et al. KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation. Bone Marrow Transplant. 2009;44(2):97–103.
Sobecks RM, Wang T, Askar M, et al. Impact of KIR and HLa genotypes on outcomes after reduced-intensity conditioning Hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(9):1589–1596, Sep.
Clausen J, Böhm A, Buxhofer-Ausch V, et al. Impact of anti-Thymocyte globulin (aTG) on overall survival depends on HLa-C group KIR ligand status – significant benefit in C1 homozygous HSCT recipients. Bone Marrow Transplant. 2015;50(S1):232.
McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024–3031.
Koreth J, Kim HT, Lange PB, et al. A Bortezomib-based regimen offers promising survival and graft-versus-host disease prophylaxis in Myeloablative HLa-mismatched and unrelated donor transplantation: a phase II trial. Biol Blood Marrow Transplant. 2015;21(11):1907–1913.
Zhang L, Chu J, Yu J, Wei W. Cellular and molecular mechanisms in graft-versus-host disease. J Leukoc Biol. 2016;99(2):279–287.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Statement for J.C.:
-
Consultation fee: Neovii Biotech
-
Speaker honorarium: Celgene
-
Advisory board: Janssen
Rights and permissions
About this article
Cite this article
Clausen, J. New approaches in graft versus host disease (GvHD) management. memo 9, 45–47 (2016). https://doi.org/10.1007/s12254-016-0259-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-016-0259-3